Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

Eli Lilly is experiencing explosive growth ... However, another star performer throughout 2024 was Verzenio -- Lilly's main oncology treatment. For the nine months ended Sept.

Verzenio's performance in 2024 underscores ... they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly ... in Lilly's weight loss portfolio. However, another star performer throughout 2024 was Verzenio -- Lilly's ...